Mad Money w/ Jim Cramer 1/13/25
Mad Money w/ Jim Cramer
Deep Dive
What is Venu's business model and how is it disrupting the live music industry?
Venu owns and operates upscale music venues and outdoor amphitheaters, generating revenue from seven different sources. With $166 million in assets and $77 million in luxury suite sales in 2024, the company is experiencing 56% year-over-year growth. It is disrupting the multi-billion dollar live music industry by offering a diversified revenue model and upscale experiences.
Why is Jim Cramer critical of the U.S. government's restrictions on NVIDIA's GPU sales?
Jim Cramer criticizes the U.S. government's restrictions on NVIDIA's GPU sales, which limit exports to all but 18 friendly nations, as short-sighted and counterproductive. He argues that these rules undermine NVIDIA CEO Jensen Huang's efforts to promote sovereign AI globally and empower other nations, rather than treating U.S. businesses as adversaries.
What is Bristol-Myers Squibb's new schizophrenia drug, and why is it significant?
Bristol-Myers Squibb's new schizophrenia drug, CoBinfi, is significant because it offers efficacy comparable to existing treatments but with far fewer side effects. It addresses unmet medical needs by improving patients' cognitive abilities and reducing symptoms like hallucinations, enabling them to reengage with their families. The drug has been well-received by physicians and patients since its launch in September 2023.
How is Boston Scientific's Farapulse system transforming the treatment of atrial fibrillation (AFib)?
Boston Scientific's Farapulse system is transforming AFib treatment by offering a safer and more efficient procedure. It reduces the risk of stroke and heart failure, allows patients to recover faster, and is 25-30% quicker than traditional methods. The system has been used in over 200,000 procedures and is expected to become the company's largest business by 2025.
What is Medtronic's new adaptive DBS technology for Parkinson's, and how does it improve patient care?
Medtronic's adaptive DBS (Deep Brain Stimulation) technology for Parkinson's automatically adjusts therapy in real-time based on brain signals, eliminating the need for episodic updates by physicians. This innovation improves patient outcomes by providing continuous, personalized treatment and reduces the burden on healthcare systems. It recently received CE mark approval in Europe.
Why does Jim Cramer believe the quantum computing bubble has burst?
Jim Cramer believes the quantum computing bubble has burst because industry leaders like NVIDIA's Jensen Huang and Meta's Mark Zuckerberg have stated that quantum computing is decades away from commercial viability. This reality check, combined with speculative trading and insider selling, has led to significant losses for companies like Rigetti Computing, which saw its stock plummet from $21 to $6.
What is the significance of Bristol-Myers Squibb's acquisition of Karuna Therapeutics?
Bristol-Myers Squibb's acquisition of Karuna Therapeutics is significant because it aims to address intractable brain diseases, such as schizophrenia, through innovative treatments. Despite skepticism about the high cost ($14 billion), the acquisition aligns with Bristol-Myers' strategy to invest in neuroscience and tackle unmet medical needs, leveraging profits from drugs like Eliquis to fund such initiatives.
How does Boston Scientific's Watchman device complement its Farapulse system for AFib treatment?
Boston Scientific's Watchman device complements its Farapulse system by further reducing the risk of stroke in AFib patients. While Farapulse treats the irregular heartbeat, Watchman allows patients to stop using blood thinners, reducing the risk of bleeding. This combination enables patients to live more active lives without the fear of stroke or bleeding complications.
- Biden administration's policies negatively impacting tech and pharmaceutical companies
- Restrictions on NVIDIA's GPU sales to limit China's access to advanced chips
- Criticism of the Inflation Reduction Act's drug pricing provisions
- Concerns about the government's treatment of businesses as the enemy
Shownotes Transcript